Staphylococcus aureus is a leading cause of nosocomial infections, especially in mechanically ventilated patients. Its remarkable potential to acquire and accumulate high-level resistance against most of the classical antibiotics (including vancomycin) used for the treatment of gram-positive infections is one of the reasons for the ongoing mortality caused by hospital-acquired S. aureus infections (7, 17) .
Daptomycin is the first of a new class of cyclic lipodepsipeptide antibiotics (Fig. 1A ) with strong bactericidal activities against gram-positive pathogens (2) . It interferes with cell envelope integrity, and cell death occurs presumably by either membrane depolarization or membrane perforation (19, 20) . Friulimicin B, an acidic, cyclic lipopeptide produced by Actinoplanes friuliensis, shows structural similarities to daptomycin (Fig. 1B) and is also active against multidrug-resistant grampositive bacteria (1, 22) .
As part of a coordinated effort to study and characterize its mode of action, we have performed comparative in-depth expression profiling for both antibiotics. This technique is a powerful approach to elucidate the inhibitory mechanisms of novel antimicrobial compounds (4, 9) and has been successfully applied to characterize and differentiate antimicrobial actions, often using Bacillus subtilis as a model organism (3, 10) . B. subtilis is particularly well suited for studying cell wall antibiotics, since the regulatory network orchestrating its cell envelope stress response (CESR) is well characterized. It consists of four two-component systems and at least four extracytoplasmic function (ECF) factors (11) .
Here, we present results from an in-depth analysis of the expression signature provoked by the treatment of B. subtilis with sublethal amounts of daptomycin and friulimicin B. Our data show that both antibiotics specifically target cell envelope integrity. But significant differences in the corresponding CESRs, as clearly documented by transcriptomics, proteomics, and detailed gene expression profiling, strongly suggest different modes of action of the two structurally related antibiotics.
(This study was presented in part at the 47th International Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17 to 20 September 2007 [25] ).
Transcriptomics and proteomics. For microarray experiments, midlogarithmic cultures of B. subtilis were challenged with 1 g/ml (sublethal amounts) of either daptomycin or friulimicin B. The cells were harvested 10 min postinduction, and cell pellets were directly snap-frozen in liquid nitrogen. RNA preparation and microarray experiments were performed essentially as described previously (13, 23) . To validate the gene expression profiles, we also performed two-dimensional gel electrophoresis of the cytoplasmic proteome of B. subtilis cells, quantifying de novo protein synthesis after the addition of daptomycin or friulimicin B by incubating the cultures in the presence of L-[
35 S]methionine, as described previously (3). The results are summarized in Table 1 and Fig. 2 . The complete microarray data sets can be found in the supplemental material and, together with additional supporting information, at http://microbial-stress.iab.kit.edu/87.php.
Both antibiotics induced a limited number of genes, most of which could be assigned to known CESR regulons. Daptomycin specifically and strongly activated the LiaRS two-component system, with more than 200-fold induction of its primary target genes, liaIH. This induction has also been observed recently in an independent study (9a) and is in good agreement with data from the orthologous VraSR system of S. aureus which was also induced by daptomycin (16) . Moreover, a strong LiaH induction was also observed with proteomics analysis, where it was identified in three strong neighboring spots (differing in their isoelectric points), indicative of posttranslational modifications (Fig. 2 ).
Both compounds induced numerous genes known to be regulated by ECF factors. This ECF-dependent response was much stronger for friulimicin B (Table 1 ). In addition, only seven genes/proteins of unknown regulation were differentially expressed (Table 1 and Fig. 2 ), including the actin homolog mreBH, which was induced about three-to fourfold by both 
a Only genes that were induced Նthreefold in three independent experiments by daptomycin and/or friulimicin B are shown. The proteins corresponding to the underlined genes were also significantly upregulated in the cytoplasmic proteome (Fig. 2) .
b Average induction ratio of the highest value for each locus (usually the first gene in an operon) and the corresponding standard deviation are given. DAP, daptomycin; FRI, friulimicin B; Ϫ, no significant induction. compounds. Five more genes without known regulator, some of which are potentially involved in cell envelope biogenesis, specifically responded to friulimicin B (Table 1 ). All genes identified in our analysis have been linked to CESR of B. subtilis previously (data not shown). While no expression signature available so far resembles that of friulimicin B, both the transcriptome and the proteome profile for daptomycin closely resemble those of bacitracin (3, 14) . In-depth gene expression profiling. The results of our microarray study led to three follow-up analyses on the specificity of the corresponding CESR. (i) We analyzed the induction of all seven ECF factors by quantitative real-time reverse transcriptase PCR (RT-PCR), based on the known and highly ECFspecific autoregulation of their own genes, to determine the respective inducer spectrum and strength. The primers used for amplification are listed in Table 2 . Both antibiotics activate M and V , with friulimicin B provoking a significantly stronger response. In addition, friulimicin B also induced the uncharacterized ECF factor YlaC (Table 3) . (ii) The much stronger activation of ECF target genes by friulimicin B was not due to the corresponding lack of liaIH induction, as demonstrated by the induction values of ECF genes in the liaIH mutant strain TMB0389, which were identical to those in the wild type (data not shown). The stronger ECF response to friulimicin B is therefore LiaIH independent and a true antibiotic-specific difference in the corresponding gene induction profiles.
(iii) We also quantified the activity of the LiaR target promoter P liaI as a function of the daptomycin/friulimicin B concentrations over a range of 4 orders of magnitude by performing a ␤-galactosidase assay (using strain BFS2470 as described previously) (15) . P liaI induction was indeed only observed in the presence of daptomycin and in a very narrow window of antibiotic concentrations (between 0.5 and 2 g/ml) (data not shown). These results strongly suggest different modes of action for daptomycin and friulimicin B.
Conclusions. Our data clearly allowed the identification of cell envelope integrity as the site of daptomycin and friulimicin B action, but the results strongly suggest mechanistic differences between the two compounds. This assumption is primarily based on the dramatic differences in the LiaRS response. Moreover, friulimicin B activates both M and V more strongly than daptomycin and, additionally, induces YlaC expression (summarized in Fig. 3) . The strong similarities of CESR between daptomycin and bacitracin were initially viewed as an indication that daptomycin might interfere with the lipid II cycle of cell wall biosynthesis. But a detailed biochemical mechanism of action study revealed that friulimicin B, like amphomycin but in contrast to the membrane-interfering daptomycin, inhibits cell wall biosynthesis by binding bactoprenol phosphate (18) . 
